New device aims to zap prostate cancer with less harm

NCT ID NCT07492381

Not yet recruiting Disease control Sponsor: ALPFA Medical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study will test a new device that uses pulsed field ablation (PFA) to treat localized prostate cancer in 50 men aged 45 or older. The goal is to see if the procedure is safe and effective at destroying cancer cells while minimizing damage to surrounding tissue. Participants will be followed for 90 days to monitor for any serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALPFA BPH PFA System (device using pulsed field ablation)
What this could lead to: If successful, this could offer a less invasive treatment option for localized prostate cancer, potentially reducing side effects compared to surgery or radiation.
What could go wrong: This is a small, early pilot study with no control group, so results may not apply broadly. The procedure carries risks of side effects like urinary or erectile problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.